{
  "docId": "019de070-35c1-7439-bbdc-1b157563e1ac",
  "docSlug": "efb4ac2b8ef2465cd20aa5f0f0b26fe6",
  "documentTitle": "Poseida Therapeutics | IPO Presentation Deck | 34 slides",
  "authorId": "poseida-therapeutics",
  "authorName": "Poseida Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 34,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a biological diagram to explain the mechanism of T-cell activation and a line chart to show the performance improvement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-35c1-7439-bbdc-1b157563e1ac/18",
  "deckHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac",
  "deckJsonHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac.json",
  "deckAnchorHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.68,
        "y": 0.38
      },
      "kind": "callout",
      "text": "With Booster: Our patented technology is designed to overcome these limitations, and significantly increase production yield while preserving desirable TSCM attributes of P-BCMA-ALLO1",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "900b2d7f-06b3-4072-81b1-81359cfa6945",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.42,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Line chart showing Fold Expansion of CAR-T production with and without Booster technology.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "512568a9-0564-4d33-9bb5-04652daa039c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Biological diagram showing T-cell activation components (CD28, CD3, TCR, CD2) and the impact of gene editing.",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5bdfc5a-7d69-46a2-829c-ab309c4285cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Our Booster Molecule Technology – Potential to Overcome the “Allo Tax” Common to Other Allogeneic CAR-T Approaches",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "362c4712-d8d5-487d-9dbb-25a96c5b80ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 11,
      "beatId": "e01fc233-3e21-43db-96cd-4c2c3ec10517",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Description of pipeline and product candidates, including CAR-T and gene therapy programs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}